Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Palliative Care Use in Advanced Renal Cell Carcinoma Linked to Socioeconomic Groups
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Race Reporting in GU Cancers Indicates Relative Overrepresentation of White Individuals
Lythgoe et al studied patterns of race reporting in genitourinary (GU) cancer trials.
Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
Effect of Hypertension History on Outcomes in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis sought to determine the effect of hypertension on overall survival, response, and progression-free survival in patients with mRCC.
NLR Rise May Predict Mortality, Treatment Failure Risks in mRCC
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
HIF-2α Inhibitor/Cabozantinib Doublet Active in Previously Treated Advanced ccRCC
Choueiri et al tested the efficacy of the investigational hypoxia-inducible factor 2α (HIF-2α) inhibitor in combination with cabozantinib.
Real-World Data: Cabozantinib Used More Commonly Than Other TKIs After Checkpoint Inhibition in mRCC
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
Nivolumab/Cabozantinib Prolongs OS in Advanced RCC With Sarcomatoid Features
CheckMate 9ER investigators assessed the efficacy of combination nivolumab and cabozantinib in the front-line sarcomatoid renal cell carcinoma (RCC) setting in an extended analysis.
Comorbidity Burden Predicts Survival in Renal Cell Carcinoma Cases
As comorbidity burden increases, so does the risk of death among patients with renal cell carcinoma, a study found.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
On the Radar for RCC in 2021: McGregor Discusses Combination Strategies, HIF-2α Inhibition, and Other Key Topics
Bradley McGregor, MD, clinical director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key topics in RCC care in 2021.
Survival in mRCC Varies By Histologic Subtype, Metastasis Site
Patterns of disease spread varied significantly among patients with clear cell, papillary, and chromophobe renal cell carcinoma and may reflect differences in disease biology, according to investigators.
Liver Metastases in Advanced GU Cancer Predict Poor Response to ICI Therapy
Patients who receive treatment with immune checkpoint inhibitors for advanced renal cell carcinoma and urothelial carcinoma are more likely to experience disease progression and death if they have liver metastases, a study found.
Opdivo Plus Cabometyx Approved for Advanced Kidney Cancer
The approval was based on data from the randomized, open-label phase 3 CheckMate-9ER.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Papillary RCC Subtype Not Predictive of Survival, Study Finds
Two subtypes of papillary RCC – type I and type II – have been previously described.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
